Avita has realized a revenue stream from the RCELL system, and its ability to expand its use promises to expand the revenues. The company realized $10.5 million in Q1 of this year, for a 40% increase over the year-ago quarter and beating the forecast by almost $260K. In his coverage of this stock for Cantor Fitzgerald, analyst Ross Osborn notes that RCELL has potential to alter the entire skin care medical field, and writes, "Our Overweight (i.e., Buy) rating is based on three key points: (1) the RECELL System is a disruptive technology, in our eyes; (2) we believe Avita is at an inflection point given that the two new expanded indications significantly increase the company's TAM (total addressable market); and (3) we view the company's shares as attractively valued."